Serum α-Tocopherol Levels Indicating Status of Oral Carcinoma Patients

Print
Published on Thursday, 08 August 2019

Abstract

Background: Epidemiological studies suggest that antioxidants may play a major role in the progression of oral cancer. Oxidative processes contribute in promoting stages of carcinogenesis, at this stage the level of antioxidants are very crucial in prevention & progression of carcinogenesis. Studies have suggested that deficiencies in antioxidant nutrient level are likely to be important risk in progression of cancer. Antioxidant nutrients, which play a crucial role against defense of pro oxidants, can be measured quantitatively. If they are reduced from the normal levels they can be supplemented.

Objective: The study was planned to evaluate the levels of non-enzymatic antioxidant, particularly vitamin E, in serum of oral cancer patients (n=100) & control subjects (n=50) in order to study its possible role in prediction & prevention of oral cancer.

Materials & Methods: Serum vitamin E levels were estimated colorimetrically (520 nms) by method of Baker & Frank (1968).

Results: A concomitant decline in vitamin E levels was noted in oral cancer patients w r t control group (p < 0.001). Similar results were obtained when grade I & II patients were compared with control (p < 0.001). Risk of oral cancer was 5.80 times more in patients with low vitamin E levels [2.588 to 12.8025 at 95% CI].

Conclusion: The low levels of α-tocopherol in patients could be either a cause or effect of oral carcinoma. Measurement of vitamin E in circulation of oral cancer patients may thus be a useful index in assessing tumor grades of patients. Further studies using a larger sample size & long-term follow-up of subjects are desirable.

 

About this publication.

See also:

- Official Web Site: The Di Bella Method;

- The Di Bella Method (A Fixed Part - Alpha tocopheryl acetate/Vitamin E, approximately 20 grams per day orally);

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- The Di Bella Method (A Fixed Part - All-Trans Retinoic Acid, Analogues and/or Derivatives - Approximately 60mg per day orally: 40mg per day Beta-Carotene/β-Carotene, 10mg per day ATRA and 10mg per day Axerophthol palmitate);

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives) - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Vitamin C/Ascorbic Acid, 2–4 grams, twice a day orally);

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- Neuroblastoma: Complete objective response to biological treatment;

- Oesophageal squamocellular carcinoma: a complete and objective response;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.